Tumors were cultured ex vivo for 7 days, and increased percentages of human CD45+ immune cells were seen in both untreated and IL-2-treated tumors from tumor-bearing mice with sNK infusion compared to untreated tumor-bearing mice (Figure 4C). This evidence concerns the gene PTPRC and neoplasm.